30 Participants Needed

RELVAR for COPD

Age: 18+
Sex: Any
Trial Phase: Phase 4
Sponsor: University of Calgary
Must be taking: Long acting bronchodilators
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This study examines the effect of the ultra long acting beta agonist/corticosteroid bronchodilator combination fluticasone furoate/vilanterol trifenatate, on respiratory muscles and ventilation in adults with severe bronchitis or emphysema (COPD).

Do I need to stop my current medications for the trial?

The trial does not specify if you need to stop your current medications, but it requires participants to be on long-acting bronchodilator therapy. It's best to discuss your current medications with the trial team.

What data supports the effectiveness of the drug RELVAR for COPD?

Research shows that the drug RELVAR, which combines fluticasone furoate and vilanterol, improves lung function and reduces flare-ups in people with COPD. It is generally well tolerated and offers the convenience of once-daily use, which may help patients stick to their treatment plan.12345

Is RELVAR safe for humans?

RELVAR, also known as Fluticasone Furoate/Vilanterol, has been generally well tolerated in studies for COPD and asthma, but there is an increased risk of pneumonia with long-term use.13467

How is the drug Fluticasone Furoate/Vilanterol unique for treating COPD?

Fluticasone Furoate/Vilanterol is unique because it combines a corticosteroid with a long-acting bronchodilator in a once-daily inhaler, which can improve lung function and reduce flare-ups more effectively than some other treatments. Its once-daily dosing may also help patients stick to their treatment plan better.13489

Research Team

PA

Paul A Easton, MD, PhD

Principal Investigator

University of Calgary

Eligibility Criteria

This trial is for adults with severe COPD who can handle a minor surgery with sedation, take their meds regularly, and are able to walk. They should be on long-term bronchodilator therapy but not have had a major flare-up in the last 2 months or serious heart issues.

Inclusion Criteria

Compliant with use of prescribed medications
I am healthy enough for a minor surgery with sedation.
I am on medication to help open my airways.
See 1 more

Exclusion Criteria

You are allergic to the combination of fluticasone furoate and vilanterol.
You are allergic to milk proteins.
I have chest pain or a high risk for heart problems.
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive inhalation of fluticasone furoate/vilanterol trifenatate, 100 mcg/25 mcg combination, using a standard dry powder inhaler

2 hours
1 visit (in-person)

Follow-up

Participants are monitored for changes in minute ventilation, parasternal EMG, and pressure with phrenic stimulation after treatment

2 hours
1 visit (in-person)

Treatment Details

Interventions

  • Fluticasone Furoate
  • Vilanterol Trifenatate
Trial Overview The study tests how fluticasone furoate/vilanterol (a long-acting inhaler medication) affects breathing muscles and overall ventilation in people with severe chronic bronchitis or emphysema, which are forms of COPD.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Fluticasone vilanterol bronchodilatorExperimental Treatment3 Interventions
Inhalation of fluticasone furoate/vilanterol trifenatate, 100 mcg/25 mcg combination, bronchodilator,using standard dry powder inhaler. Interventions include ventilation, parasternal EMG, and phrenic magnetic stimulation.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Calgary

Lead Sponsor

Trials
827
Recruited
902,000+

Findings from Research

In a 6-year observational study involving 3426 patients with asthma and/or COPD, fluticasone furoate/vilanterol (FF/VI) demonstrated a good safety profile, with an overall adverse event rate of 30.9% and serious adverse events occurring in only 4.1% of patients.
FF/VI was effective in improving lung function, with significant increases in forced expiratory volume in 1 second (FEV1) observed in patients with asthma (0.09 L), COPD (0.11 L), and those with both conditions (0.05 L), indicating its efficacy in real-world settings.
Real-World Safety and Effectiveness of Fluticasone Furoate/Vilanterol in Patients with Asthma and/or Chronic Obstructive Pulmonary Disease: A Post-Marketing Study in Korea.Cho, EY., Cho, JE., Jang, SH., et al.[2023]

References

Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease. [2021]
A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD. [2018]
Real-World Safety and Effectiveness of Fluticasone Furoate/Vilanterol in Patients with Asthma and/or Chronic Obstructive Pulmonary Disease: A Post-Marketing Study in Korea. [2023]
A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. [2022]
Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease. [2014]
Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. [2022]
Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial. [2022]
Short- and long-term effects of fluticasone furoate/vilanterol in exercising asthmatic adolescents: A randomized and open label trial. [2022]
Fluticasone furoate/vilanterol: a review of its use in patients with asthma. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security